A randomized phase II study of paclitaxel (P) and carboplatin (C) ± bevacizumab (B) ± dulanermin (D) in non-small cell lung cancer (NSCLC). A multicenter phase II randomized study of docetaxel ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results